Cargando…
The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
New targets for Ewing sarcoma (ES) patients are urgently needed. Therefore, we investigated the expression and genetic aberrations of the oncogenic receptor tyrosine kinase (RTK) AXL in ES and determined the efficacy of AXL targeting on cell viability and migration. First, AXL and Gas6 (ligand) mRNA...
Autores principales: | Fleuren, Emmy D.G., Hillebrandt-Roeffen, Melissa H.S., Flucke, Uta E., te Loo, D. Maroeska W.M., Boerman, Otto C., van der Graaf, Winette T.A., Versleijen-Jonkers, Yvonne M.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350331/ https://www.ncbi.nlm.nih.gov/pubmed/25528764 |
Ejemplares similares
-
Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma
por: van Erp, Anke E. M., et al.
Publicado: (2022) -
Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy
por: Oien, Derek B., et al.
Publicado: (2018) -
Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas
por: Weidema, Marije E., et al.
Publicado: (2019) -
Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
por: Vlenterie, Myrella, et al.
Publicado: (2016) -
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)